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Abstract
Understanding the mechanistic basis of prodrug delivery and activation is critical for establishing 
species-specific prodrug sensitivities necessary for evaluating pre-clinical animal models and 
potential drug-drug interactions. Despite significant adoption of prodrug methodologies for 
enhanced pharmacokinetics, functional annotation of prodrug activating enzymes is laborious and 
often unaddressed. Activity-based protein profiling (ABPP) describes an emerging 
chemoproteomic approach to assay active site occupancy within a mechanistically similar enzyme 
class in native proteomes. The serine hydrolase enzyme family is broadly reactive with reporter-
linked fluorophosphonates, which have shown to provide a mechanism-based covalent labeling 
strategy to assay the activation state and active site occupancy of cellular serine amidases, 
esterases, and thioesterases. Here we describe a modified ABPP approach using direct substrate 
competition to identify activating enzymes for an ethyl ester prodrug, the influenza neuraminidase 
inhibitor oseltamivir. Substrate-competitive ABPP analysis identified carboxylesterase 1 (CES1) 
as an oseltamivir-activating enzyme in intestinal cell homogenates. Saturating concentrations of 
oseltamivir lead to a 4-fold reduction in the observed rate constant for CES1 inactivation by 
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fluorophosphonates. WWL50, a reported carbamate inhibitor of mouse CES1, blocked oseltamivir 
hydrolysis activity in human cell homogenates, confirming CES1 is the primary prodrug activating 
enzyme for oseltamivir in human liver and intestinal cell lines. The related carbamate inhibitor 
WWL79 inhibited mouse, but not human CES1, providing a series of probes for analyzing 
prodrug activation mechanisms in different preclinical models. Overall, we present a substrate-
competitive activity-based profiling approach for broadly surveying candidate prodrug 
hydrolyzing enzymes and outline the kinetic parameters for activating enzyme discovery, ester 
prodrug design and preclinical development of ester prodrugs.
Keywords
prodrug; ethyl ester hydrolysis; activation; activity-based protein profiling; SILAC; 
carboxylesterase
INTRODUCTION
Prodrug development typically begins with pre-clinical studies in mice, which are later 
extrapolated to predict efficacy in humans. Unfortunately, this process is complicated by 
interspecies differences in expression and significant genetic polymorphisms present across 
activating enzyme orthologues1. Early knowledge of specific activation pathways would 
accelerate this process, enabling direct assessment of species-specific prodrug activation 
pathways. While this is an important goal, traditional activity-guided biochemical 
fractionation and lengthy identification procedures hinder the annotation of prodrug 
activating enzymes. New methods for simplified identification of prodrug hydrolyzing 
enzymes would aid in the development, targeting, and optimization of new prodrug 
strategies.
The human genome encodes approximately 200 members of the serine hydrolase enzyme 
family, which carry out catalytic roles as amidases, esterases, and thioesterases of diverse 
cellular substrates2, 3. Since many prodrug moieties involve esterification or amidation, it is 
not surprising that serine hydrolases are often implicated in the catabolism and activation of 
distinct prodrugs. As many of these enzymes remain unannotated, biochemical fractionation 
is the most common approach to identify candidate prodrug hydrolyzing enzymes. We 
previously used such methods to identify valacylovirase (BPHL)4, the activating enzyme for 
the orally absorbed antiviral prodrug valacyclovir. Astonishingly, BPHL was first identified 
8 years after valacyclovir FDA approval, demonstrating the significant obstacles for 
mechanistic analysis of prodrug uptake pathways. Similarly, the prodrug activating enzymes 
for dabigatran etexilate were reported nearly 12 years after its initial pre-clinical 
discovery5, 6. With the annotation of the physiological prodrug activating enzymes, new 
opportunities arise to profile expression, activity, evolutionary conservation, and distinct 
polymorphisms that help design modes of delivery, optimize biodistribution, and effectively 
model pharmacokinetics. These examples highlight the present challenges in developing a 
mechanistic understanding of prodrug activation in drug delivery.
Activity-based protein profiling (ABPP) describes the use of reporter-linked covalent 
inhibitors to profile abundance, activation state, and the active-site occupancy across a 
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mechanism-specific enzyme class. ABPP probes only react with functional and accessible 
reactive centers, and labeling is occluded by active site inhibitor occupancy. Since labeling 
is covalent, a reporter group (fluorophore, biotin, etc.) is irreversibly attached to its target 
enzymes, providing a chemical handle to visualize active enzymes using gel-based 
fluorescence, or assess active-site competitive occlusion by mass spectrometry-based 
proteomics. Importantly, activity-based profiling does not require purified enzymes or 
tailored substrate assays, enabling direct active-site interrogation in native lysates. Activity-
based probes have been extensively developed for many enzyme families7, including serine 
hydrolases2, 8, cysteine hydrolases9, and protein kinases10. In addition to profiling active 
hydrolases in complex proteomes, ABPP methods are especially useful for selectivity-
guided medicinal chemistry, where stepwise competitive profiling highlights off-targets for 
optimization based on both potency and selectivity in native proteomes11, 12.
While competitive ABPP methods provide a robust approach for the discovery of active-site 
inhibitors, several considerations must be recognized to successfully profile targets of 
competitive, reversible inhibitors. Unlike competitive inhibitors, covalent inhibitors compete 
with activity-based probes in a non-equilibrium, time-dependent manner, which complicates 
profiling active site occupancy of moderate affinity ligands. To overcome this challenge, 
one solution is to weaken the potency of the ABPP probe using chemical modifications that 
preclude rapid enzyme inactivation. This kinetically-tuned competitive ABPP strategy was 
used to evaluate in vivo selectivity and tissue distribution of several reversible 
lysophospholipase inhibitors13.
Based on these findings, we sought to extend this methodology to proteome-wide substrate-
competitive profiling. When the off-rate associated with initial substrate binding is much 
greater than the rate of enzyme catalysis, the Km is roughly a measure of a substrate's 
binding affinity for the enzyme's active site. When more than one enzyme shares a common 
substrate, the enzyme with the highest substrate affinity is likely the first to reach active-site 
saturation. Once saturated, substrate turnover is restricted by the rate-determining enzymatic 
step characterized by the unimolecular rate constant kcat. Therefore, we reasoned that time-
dependent, substrate-directed activity-based probe competition would allow identification of 
candidate prodrug activating enzymes with both reasonably low Km and kcat values for a 
given prodrug. We recently demonstrated that high concentrations of the ester prodrug 
enalapril sufficiently compete for active site occupancy and impede fluorophosphonate 
inactivation of recombinant CES114. Given these steady-state kinetic parameters, the 
success of this method relies on rapid incubation times (seconds to a few minutes) and 
optimized probe concentrations, as an irreversible active site probe will react to completion 
and eventually eliminate any observable differences13, 14.
Using this approach, we demonstrate that saturating concentrations of the ethyl ester prodrug 
oseltamivir reduced fluorophosphonate labeling of specific targets in cellular homogenates. 
Human liver carboxylesterase 1 (CES1) is a known activating enzyme of several ester 
prodrugs, including oseltamivir5, 15-18. The co-expression of multiple carboxylesterase 
(CES) genes19, 20 and the differential substrate preferences between species complicates 
direct analysis of contributions from distinct CES enzymes. To address this issue, we 
profiled a subset of reported mechanism-based covalent mouse CES1 inhibitors, 4-fluoro-3-
Xu et al. Page 3
Mol Pharm. Author manuscript; available in PMC 2015 December 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
methylphenyl cyclohexylcarbamate (WWL50) and phenyl (3-morpholinopropyl)carbamate 
(WWL79)21. Quantitative mass spectrometry and kinetic assays confirmed WWL50 
potently inactivates CES1, CES2, and the highly related, human-specific carboxylesterase, 
CES1P1. Interestingly, WWL79 only inhibits mouse CES1, and has little effect on human 
CES1, which we extrapolate from homology modeling to result from a more restrictive and 
hydrophobic active site. Therefore, the CES1 inhibitors WWL50 and WWL79 are useful 
tools for defining species-specific CES1 ester prodrug activation pathways. Overall, we 
demonstrate substrate-competitive ABPP can be used to quickly identify substrate-enzyme 
pairs in the context of a complex proteome, opening new opportunities to couple prodrug 
development with mechanistic analysis of enzymatic activation pathways.
EXPERIMENTAL SECTION
Materials
Oseltamivir phosphate (Allichem), enalapril maleate salt (Sigma-Aldrich), tazarotene 
(Selleckchem), benazepril HCl (Selleckchem), human carboxylesterase 1b (Corning), and 
carboxylesterase 2 (corning) were purchased from commercial sources. FP-PEG-TAMRA, 
FPPEG-biotin and FP-TAMRA were prepared as previously described14, 22. WWL50 and 
WWL79 were synthesized according to reported methods (Supplementary Methods).
Cell culture, lysis, and fractionization
The human colon carcinoma cell line Caco-2 (from ATCC, HTB-37) and human liver 
hepatocellular carcinoma cell line HepG2 (from ATCC, HB-8065) were cultured separately 
in complete medium (DMEM with 1% nonessential amino acid and 10% FBS) in 100 mm 
tissue culture dishes in an atmosphere of 5% CO2 at 37 °C. Cells were grown 13-14 days 
post-confluence and collected in ice-cold 50 mM Tris buffer (pH 7.4) for immediate dounce 
homogenization, followed high speed (100,000 × g for 45 min) to separate soluble (S100) 
and insoluble (P100) fractions. Protein sample concentrations were normalized using the 
BCA assay and stored at −80 °C before use.
Prodrug hydrolysis assays
Caco-2 S100 and P100 fractions (1 mg/mL) in 50 mM Tris buffer (pH 7.4) were treated with 
DMSO (0.5%) as control, FP-PEG-TAMRA (4 μM or as noted in figures), WWL50 (10 
μM), or WWL79 (10 μM) for 30 minutes at room temperature. Prodrugs were added for the 
indicated times and the reactions were terminated with two volume equivalents of 
acetonitrile (ACN) with 0.1% TFA. Precipitated proteins were removed by centrifugation 
(13,200 × g for 3 min) at room temperature, and the supernatant collected and added to 
Microplate PVDF filter. The filtrates were injected using an Agilent 1100 HPLC system 
onto a 4.6 × 150 mm 3.5 micron ZORBAX Eclipse XDB-C18 column (Agilent) and 
separated with an 11 min gradient from 2% - 90% buffer B (Buffer A: H2O with 0.1% TFA; 
Buffer B: ACN with 0.1% TFA). Products were monitored by UV absorption (220 nm for 
oseltamivir and enalapril, 254 nm for other prodrugs). Hydrolysis rates were calculated by 
integrating the relative areas under the curve.
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CES1 transient kinetic analysis—Recombinant human carboxylesterase 1 (100 nM, 
6.25 mg / L) was incubated with oseltamivir (10 mM) or vehicle (DMSO) for 8 min at room 
temperature in TBS-F127 buffer (50 mM Tris, 150 mM NaCl, 0.5 g / L Pluronic F127, pH 
7.4), followed by the addition of FP-PEG-TAMRA (1 μM). At the indicated time points, 20 
μL of reaction mixture was taken and inactivated with 4 μL of 6 × Laemmli sample buffer 
and heated at 85°C, for 5 min. Mixtures were separated by SDS-PAGE using a 4% - 20% 
precast Tris-Glycine gel (Invitrogen) and imaged using a Typhoon 9200 fluorescence 
scanner. The fluorescence intensity of each band was quantified using ImageJ and data 
fitting was performed in GraphPad Prism 6. Non-linear regression analysis was used to fit 
the data to a first-order exponential curve of the form F(t) = Ffinal * (1 – exp(–kobs * t), 
where F(t) is the fluorescence intensity at a given time, kobs is the observed pseudo-first 
order rate constant and t is reaction time.
CES1 steady-state kinetic analysis
Purified recombinant human carboxylesterase 1 (160 nM, 10 mg / L) was incubated with 
varying concentrations of oseltamivir (0.2 – 5 mM) in Tris buffer (50 mM, 100 μg / ml BSA, 
pH 7.4). A sample of the reaction mixture (30 μL) was removed at 0, 5, 10, 15 and 20 min 
post initiation and quenched in 60 μL of acetonitrile with 0.1% TFA. Mixtures were 
separated on an HPLC (Agilent 1100) equipped with a 4.6 × 150 mm 3.5 micron ZORBAX 
Eclipse XDB-C18 column using an acetonitrile gradient (11 min gradient from 2% - 90%). 
Relative levels of substrate and product were calculated by integrating the corresponding 
chromatographic peaks. The rate of product formation at each substrate concentration was 
obtained by measuring the slope associated with the time-course and data fitting was 
performed in GraphPad Prism 6. Non-linear regression analysis was used to fit the data to 
the steady-state Michaelis-Menten equation.
Substrate-competitive activity-based protein profiling
Oseltamivir competition assays were performed by first incubating proteome aliquots (1 
mg / mL final) with oseltamivir (10 mM) for 10 min at room temperature in 50 mM Tris 
buffer (pH 7.4). FP-PEG-TAMRA was then added at room temperature for less than 5 
minutes and quenched with sample loading buffer at 85 °C for 5 min, followed by SDS-
PAGE analysis (4% - 20%, Tris-Glycine Pre-cast gel (Invitrogen)) and visualized on-gel in a 
Typhoon 9200 fluorescence imager. For competitive activity-based selectivity assays, 
proteome samples (1 mg / mL in 50 mM Tris buffer, pH 7.4) were incubated with WWL79 
or WWL50 at varying concentrations for 30 min at room temperature, followed by addition 
of FP-PEG-TAMRA (4 μM) for 30 minutes, separated by SDS-PAGE, and analyzed by in-
gel fluorescence analysis.
ABPP-SILAC analysis
Caco-2 cells were passaged more than 6-times in SILAC-DMEM (Thermo) supplemented 
with either 100 μg/ml of 12C6 14N2-lysine and 12C6 14N4-arginine (LIGHT condition) 
or 13C6 15N2-lysine and 13C6 15N4-arginine (HEAVY condition), 10% dialyzed FBS (JR 
Scientific), and 1x penicillin/streptomycin (Life Technologies). Fractionated lysates were 
adjusted to final protein concentration of 1.5 mg / mL. Light and heavy fractions (1.5 mL 
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each) were incubated separately with WWL50 (15 μM) or vehicle for 30 min, followed by 
addition of FP-PEG-biotin (7.5 μM) for 1 hour. Light and heavy proteomes were then mixed 
in a 1:1 ratio and precipitated by chloroform: methanol extraction (1.5 vol CHCl3 : 4 vol 
MeOH : 3 vol water) , briefly vortexed, and centrifuged (10,000 × g) at room temperature 
for 10 min to separate the aqueous and organic phases. The top aqueous phase was carefully 
discarded, followed by addition of an additional 3 volumes of methanol and centrifugation 
(10,000 × g, 10 min). The resulting protein precipitate was then mixed with 4 volumes of 
methanol (6 mL) and sonicated at 4 °C until homogenous. The protein precipitate was 
centrifuged (10,000 × g, 10 min), decanted, air-dried for 2-3 min, and re-solubilized in 500 
μL of 6 M urea / 50 mM ammonium bicarbonate buffer. The sample was then reduced with 
DTT (10 mM, 65 °C, 15 min) and alkylated with iodoacetamide (40 mM, room temperature, 
30 min, in dark). Next, 140 μL of 10% SDS was added and the protein mixture was 
incubated at 65 °C for 10 min., followed by dilution with 5.5 mL of PBS buffer. Once 
cooled, streptavidin-agarose resin (Thermo Scientific, 50% slurry, 200 μL) was added and 
rotated at room temperature for 1.5 hour. After binding to streptavidin beads, the supernatant 
was removed and the resin was washed three times with 1% SDS in PBS buffer (200 μL) 
and three times with PBS buffer (200 μL). On-bead digestion was performed for 12 h at 37 
°C with trypsin (Promega) in the presence of CaCl2 (2 mM). Peptide samples diluted to a 
final concentration of 30-50 ng / μL with 5% (v / v) formic acid.
Mass Spectrometry and Data Analysis
Tryptic digests were separated using a Waters NanoAcquity UPLC system equipped with a 
5 μm Symmetry C18 (180 μm × 20 mm) trap column and a 1.8 μm High Strength Silica 
(HSS-T3) analytical column (75 μm × 150 mm) heated to 35 °C coupled to a picotip emitter 
(New Objective). Tryptic peptides were loaded onto the trap column over 3 minutes, 
followed by analytical separation over a 90 minute gradient (3% acetonitrile to 40% 
acetonitrile over 90 minutes). Peptides were analyzed using a Waters Synapt G2S HDMS 
time-of-flight mass spectrometer with ion mobility separation and data independent 
fragmentation algorithms. The quadruple mass analyzer was manually set for mass 500, 600 
and 700. The sampling cone was adjusted to 32 eV and the nano flow gas was set to flow at 
0.2 bar. The purge gas was set to flow at 50 L / h and the source temperature was set at 70 
°C. For all measurements, the mass spectrometer was operated in V-mode (resolution mode) 
with a resolving power of at least 20,000 FWHM (full width at half maximum) in positive-
mode ESI. The time-of-flight analyzer of the mass spectrometer was calibrated with a 100 
fmol / μL solution of [Glu1]-Fibrinopeptide B from m/z 50 to 1250 to within 0.5 ppm. The 
data was corrected in post-acquisition analysis using the doubly charged monoisotopic ion 
of [Glu1]-Fibrinopeptide B (m/z = 785.8426) collected every 30 seconds from a separate 
calibrant fluidics source coupled to a tapertip emitter (New Objective). Accurate mass data 
was collected in data-independent acquisition (DIA) mode in combination with in-line ion 
mobility separation (IMS). For IMS, the wave height was set as 40 V and IMS wave 
velocity as 600 m/s. The spectral acquisition time in each mode was 0.5 s. In low-energy MS 
mode, data were collected without applying collision energy in the trap or the transfer stage. 
A collision energy (CE) ramp from 15 eV to 45 eV during each 0.5 s-integration was used as 
standard setting for the elevated energy MS scan in the transfer region for HDMSE mode. 
LC-MS spectra were collected in continuum mode and searched using the ProteinLynx 
Xu et al. Page 6
Mol Pharm. Author manuscript; available in PMC 2015 December 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Global SERVER version 3.0.2 (Waters) against the reviewed human reference proteome 
(UniProtKB downloaded on 2014-08-01). Precursor- and fragment-ion mass tolerances were 
automatically determined by PLGS 3.0.2 based on the following search criteria: (i) trypsin 
as digestion enzyme, (ii) a maximum of one missed cleavage, (iii) lysine (+8) or arginine 
(+10) defined as fixed modifier reagent groups, (iv) carbamidomethyl cysteine as a fixed 
modification and methionine oxidation as the variable modification, (v) a minimum of two 
identified fragment ions per peptide and a minimum of five fragments per protein, and (vi) 
at least two identified peptides / protein. The false discovery rate (FDR) for peptide and 
protein identification was set at 1% using a reversed database. Using in-house Python 
scripts, all data from technical and biological replicates were merged, removing any 
precursors greater than ± 10 ppm in mass difference from the calculated theoretical mass. 
SILAC ratios were computed based on MS1 intensities of the SILAC precursor pairs. All 
reported ratios in the manuscript are consolidated ratios from runs in each direction and 
from merging technical replicates.
Homology Modeling and Covalent Docking
The homology model of mouse CES1 was built using chain A of the crystal structure of 
human CES1 (PDB ID: 2H7C) as a template. 2H7C has the highest resolution (2Å) of all the 
available human CES1 crystal structures. The homology model was built using Prime23, 24 
from the Schrodinger software suite. To prepare human and mouse CES1s for covalent 
docking, each protein was processed with the Protein Preparation Wizard to add hydrogens 
and address histidine tautomers and asparagine and glutamine flips where necessary. The 
carbamate bond to be broken in WWL50 and 79 for covalent docking was specified using a 
SMARTS string. The shape and volume of the ligand free binding site was generated with 
the program HOLLOW25 using a grid spacing of 0.25 Å and covalently docked models 
along with the volume of the binding site were rendered using PyMOL.
RESULTS
Substrate-competitive profiling of oseltamivir-binding serine hydrolases
Ethyl ester hydrolysis of oseltamivir is necessary to liberate the active carboxylate essential 
for neuraminidase inhibition26 (Figure 1A). CES1 has been previously biochemically 
characterized as an oseltamivir-activating enzyme, yet human CES1 polymorphisms do not 
account for all of the variability in patient prodrug activation27. Under the background of 
this model, we sought to establish if substrate-competitive activity-based profiling could 
directly annotate oseltamivir-activating enzymes among serine hydrolases present in human 
Caco-2 cell homogenates, a cell line that expresses multiple carboxylesterases28 and is 
widely used for modeling human intestinal absorption29. Using this system, FP-PEG-
TAMRA completely blocked oseltamivir activation, confirming members of the serine 
hydrolase enzyme family are solely responsible for ethyl ester hydrolysis (Figure 1B).
Next, Caco-2 soluble and insoluble homogenates were incubated with excess oseltamivir 
along with time-dependent addition of FP-PEG-TAMRA11, which enables in-gel analysis of 
serine hydrolase activities using a flatbed fluorescence gel scanner. After one minute of 
competition, inhibition was detectable for both a 30 kD and 60 kD enzyme (Figure 1C). 
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Both activities partitioned with the soluble (S100) (Figure 1D) and insoluble (P100) 
proteome fractions (Figure 1E). Interestingly, the 60 kD enzyme, but not the 30 kD enzyme, 
lost time-dependent competitive inhibition after 1 minute. In addition, higher FP-PEG-
TAMRA concentrations reduced oseltamivir competition for the 60 kD enzyme 
(Supplementary Figure 1), but had little effect on the 30 kD enzyme. Taken together, these 
data demonstrates that high concentrations of oseltamivir can compete for active site 
occupancy with the ABPP probe FP-PEG-TAMRA in a complex proteome. Furthermore, 
this assay identifies targets likely inhibited by oseltamivir (30 kD enzyme) as well as 
candidate activating enzymes (60 kD enzyme). Importantly, such rapid fluorophosphonate 
labeling reduces the profile of detectable targets, biasing the profile towards abundant or 
highly FP-reactive enzymes.
Oseltamivir is hydrolyzed by CES1
CES1 was previously reported as an oseltamivir hydrolyzing enzyme, and likely 
corresponds to the 60 kD molecular weight enzyme identified by gel-based substrate-
competitive ABPP. In order to validate the 60 kD enzyme as CES1, we synthesized two 
recently reported mouse CES1 covalent inhibitors, WWL50 and WWL79 for further 
analysis (Figure 2A). Each inhibitor was added at room temperature to Caco-2 homogenates 
for 30 minutes, followed by FP-PEGTAMRA labeling for an additional 30 minutes. Gel-
based competitive ABPP analysis revealed complete inhibition of the 60 kD enzyme by 
WWL50, but essentially no effect by WWL79 (Figure 2B). Neither inhibitor affected the 30 
kD band shown to be sensitive to oseltamivir. Additionally, WWL50 is nearly 100-times 
more potent towards human CES1 (IC50 = 4.3 ± 0.6 nM) than human CES2 (IC50 = 429.0 ± 
2.6 nM) (Figure 2C).
While WWL50 appears highly selective by gel-based competitive ABPP, we profiled 
selectivity against other less abundant WWL50 targets by mass spectrometry. Using stable 
isotope labeling by amino acids in cell culture (SILAC), Caco-2 cells were labeled with 
media supplemented with either normal or isotopically-heavy (Lys8, Arg10) amino acids for 
several passages. After separate treatment with either DMSO or WWL50, SILAC pairs of 
soluble and insoluble homogenates were labeled with FP-PEG-biotin and mixed in a 1:1 
ratio. Following streptavidin enrichment and trypsin digestion, eluted tryptic peptides were 
analyzed by high-resolution mass spectrometry to quantify targets of WWL50 inhibition30. 
Any hydrolase inactivated by WWL50 is unreactive with fluorophosphonate-linked biotin, 
reducing streptavidin enrichment in one of the paired samples. This difference is measured 
by quantifying the ion peak area for each hydrolase peptide in both the isotopically light and 
heavy samples, generating a relative enrichment ratio correlated with WWL50 inhibition. Of 
the 41 quantified hydrolases in Caco-2 cells, WWL50 exclusively blocked the enrichment of 
CES1, CES2, and CES1P1 (Figure 3 and Supplementary Tables 1-2). Summed across 
reciprocal replicates (DMSO-Light/WWL50-Heavy and WWL50-Light/DMSO-Heavy), 
CES1 had 138 quantified SILAC peptide pairs, while CES1P1 had 15, and CES2 had just 6, 
signifying the relative abundance of each enzyme. Based on these findings, CES1 is the 
predominant WWL50 target in Caco-2 cells contributing to oseltamivir hydrolysis.
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Next, the contribution of CES1 to oseltamivir hydrolysis was measured in Caco-2 or liver 
HepG2 cell homogenates treated with carboxylesterase inhibitors (Figure 4 and 5A). 
Hydrolytic activity was roughly similar in both soluble (S100) and insoluble (P100) 
fractions, tracking with CES1 partitioning. Incubation with either FP-PEG-TAMRA or 
WWL50 completely abolished oseltamivir hydrolysis activity (>95%), while WWL79 
showed fractional inhibition in Caco-2 homogenates. Collectively, these data confirm that 
CES1 is the primary oseltamivir hydrolase in HepG2 and Caco-2 homogenates, excluding 
contributions from the oseltamivir-sensitive 30 kD enzyme observed by substrate-
competitive ABPP. Similarly, activation of the ester prodrugs enalapril, benazepril, and 
tazarotene was also eliminated by WWL50 in both soluble (S100) (Figure 5D) and insoluble 
(P100) fractions (Figure 5E). Importantly, valacyclovir activation was unaffected by 
WWL50, as the primary activating enzyme is valacyclovirase (BPHL), which is not 
inhibited by WWL50 or FP-PEG-TAMRA.
Kinetic parameters for substrate-competitive ABPP
As the primary activating enzyme of oseltamivir, CES1 is a promising model to define the 
kinetic parameters necessary for profiling prodrug-activating enzymes by substrate-
competitive ABPP. Steady-state kinetic analysis of CES1-catalyzed oseltamivir hydrolysis 
was performed by measuring the rate of product formation in a discontinuous 
chromatographic assay. At a given substrate concentration, samples from the reaction 
mixture were taken at specific intervals and were subjected to HPLC separation and 
quantified by UV absorbance. CES1 showed surprisingly poor activity with oseltamivir, 
with KM and kcat values determined as 2.9 × 10−3 M and 0.75 s−1 respectively. The 
calculated catalytic efficiency (kcat / KM) value is 258.6 s−1·M−1, defining oseltamivir as a 
relatively poor substrate for CES1 (Figure 6A), yet not uncommon for enzymes operating in 
secondary metabolism31. Despite these obstacles, substrate-competitive occupancy is still 
observed under saturating conditions. In this case, the slow kcat likely enhances competition 
by extending substrate active site residency time.
In order to confirm substrate-competitive fluorophosphonate inactivation, time-dependent 
assays were performed using in-gel fluorescence of FP-PEG-TAMRA labeled CES1 (Figure 
6B and Supplementary Figure S2). In the presence of excess fluorophosphonate, the time-
dependent labeling of recombinant CES1 by FP-PEG-TAMRA followed pseudo-first-order 
reaction kinetics with an observed rate constant (kobs) of 4 s−1, yielding an inactivation rate 
constant (kinact = kobs/[I]) of 4.0 × 106 s−1·M−1. This value that is 15,000-times larger than 
the pseudo-second-order rate constant of CES1 for oseltamivir (kcat/KM = 258.6 s−1·M−1). 
Given the rapid kinact value, fluorophosphonate-labeled CES1 fluorescence was detectable 
after 5 seconds, and nearly saturated by 1 minute. We envisioned that under fully saturating 
substrate conditions, the rate of fluorophosphonate inactivation is limited by the rate at 
which CES1 clears its active site by turning over oseltamivir, represented by kcat. Thus, at 
oseltamivir saturation, the maximum theoretical reduction in the observed rate constant of 
FP-PEG-TAMRA labeling is 5.3-fold, or kobs/kcat. Indeed, in the presence of excess prodrug 
(c.a. 3-times the KM), we observed a 4-fold reduction in the FP-PEG-TAMRA binding rate 
constant (k’obs). Accordingly, the magnitude of substrate-competitive ABPP is highly 
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dependent on the rate of ABPP probe inactivation (kinact), the concentration of ABPP probe, 
the substrate Km, the substrate kcat, the substrate concentration, and the probe reaction time.
Comparison of mouse and human CES1 inhibitors
WWL50 and WWL79 are potent inhibitors of mouse CES1, yet only WWL50 inhibits 
human CES1. Human and mouse CES1 are only 74% similar in amino acid sequence, 
suggesting significant evolutionary drift and potentially divergent substrate profiles. In order 
to understand the mechanism of substrate specificity, we used the reported human CES1 
crystal structure PDB ID: 2H7C)32 to build a homology model of mouse CES1 (UniProtKB 
ID: Q8VCC2). The covalent acylation products of WWL50 and 79 were modeled as adducts 
to the nucleophilic serine. Following minimization, the binding site volume of mouse CES1 
appears significantly larger, suggesting access to a broader profile of substrates. While 
several residues contribute the volume increase, human Ile358 occupies more volume than 
mouse Leu358. Accordingly, the considerably larger alkyl morpholino group in WWL79 
projects into the phenoxy binding site, occluding inhibitor binding (Figure 7B). In addition, 
mouse Arg460 is well positioned to solvate the WWL79 morpholino group through a 
bridging water molecule (Figure 7D), but the corresponding human Lys460 is oriented away 
from this region. Reported structure-activity relationship studies using phenol groups 
projecting into the alkylaminoacyl binding site led to a complete loss of human CES1 
binding33, presumably because of a lack of solvation in a hydrophobic environment. Taken 
together these results suggest that the differences between human and mouse CES1s are due 
to hydrophobicity and binding site volume.
DISCUSSION
Identifying prodrug-activating enzymes is critical to understand the factors that contribute to 
drug delivery and drug efficacy, yet this analysis tends to occur late or as an afterthought in 
the drug development pipeline. This lag is partly a result of the typical late stage 
implementation of pro-moieties to modify biopharmaceutical properties and the time-
consuming biochemical separations and assays required for validation. However, with easy 
access to human and animal genomic and proteomic information, this process can be greatly 
accelerated. In this report, we describe a substrate-competitive ABPP approach to profile 
cellular serine hydrolases that bind a prodrug, and measure this binding through competition 
with broadly reactive chemical reporters targeting the serine hydrolase enzyme family. This 
method combines gel-based competitions with mass spectrometry protein identification, 
greatly accelerating the annotation of candidate prodrug binding enzymes. Further 
biochemical analysis is still required to confirm the enzymatic activity, and when available, 
selective inhibitors enable direct validation.
While this approach appears relatively straightforward, the time-dependent nature of the 
assay has some limitations. First, short ABPP probe reaction times are necessary to capture 
the kinetic window of substrate-mediated ABPP inhibition. Indeed, FP-PEG probes react 
exceptionally fast with CES1, making it experimentally challenging to capture the initial 
kinetic window of competition and surprisingly difficult to quantify by mass spectrometry-
based competitive ABPP profiling. Unfortunately, this rapid competition may also prevent 
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the detection of substrate saturation for many enzyme reactive sites, obscuring less abundant 
hydrolases and reducing the limit of detection. Second, the affinity and reactivity of distinct 
ABPP probes towards different enzymes exhibit variable kinetic parameters. Therefore, 
more exhaustive profiling may require a series of kinetically-tuned reactive probes with 
different enzyme preferences13, preferably with slower kinact rate constants. Finally, certain 
enzymes may interact with substrates via a competitive or mechanism-based mode of 
inhibition rather than catalyzing their turnover, thus requiring additional time-dependent 
analysis to distinguish substrate targets from true activating enzymes.
An alternative forward-genetics approach would involve overexpression or knockdown of 
all serine hydrolases for activity-guided assessment of the binding enzymes. Over-expressed 
enzymes could be tested without purification using the substrate-competitive ABPP 
methodology34. In addition, a set of generic serine hydrolase inhibitors could be examined, 
which in combination with ABPP methods, could quickly reduce the number of candidate 
activating enzymes. While our competitive analysis identified more than one oseltamivir 
binding hydrolase, CES1 inhibition alone accounted for >95% of oseltamivir hydrolysis 
activity in intestine and liver derived cell lines. This suggests that oseltamivir is a 
mechanism-based inhibitor of at least one serine hydrolase (30 kD enzyme), although not an 
efficient substrate.
All together, substrate-based ABPP provided a simplified approach to gather initial data 
suggestive of the candidate oseltamivir-activating enzyme. While subsequent confirmation 
of enzymatic activity is required, substrate-competitive ABPP provides a broad rapid survey 
of candidate prodrug activating enzymes. We anticipate this approach could be applied to 
annotate other uncharacterized prodrug activating enzymes, providing a preliminary screen 
to highlight candidate enzymes. Finally, using gel-based and mass spectrometry competitive 
ABPP approaches, we validate the species-specific inhibition profile of WWL50 in Caco-2 
and HepG2 cells, establishing a useful new probe for mechanistic studies on CES1-activated 
ester prodrugs.
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Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS
ABPP activity-based protein profiling
FP fluorophosphonate
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FP-PEG-TAMRA fluorophosphonate-polyethylene glycol-
carboxytetramethylrhodamine
CESs carboxylesterases
SHs serine hydrolases
ABPP-SILAC competitive ABPP with stable isotope labeling by amino acids in 
cell culture
HepG2 human hepatocellular carcinoma
Caco-2 human colorectal adenocarcinoma
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
DMEM dulbecco's modified eagle medium
FBS fetal bovine serum
DTT dithiothreitol
ESI electrospray ionization
IMS ion mobility separation
CE collision energy
FDR false discovery rate
SEM standard error of mean
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Figure 1. Competitive activity-based profiling of serine hydrolase activities in in Caco-2 
homogenates
(A) Activating esterases hydrolyze oseltamivir to release active oseltamivir carboxylate. (B) 
Oseltamivir hydrolysis is blocked in Caco-2 homogenates after fluorophosphonate (FP) 
treatment. (C) Time-dependent oseltamivir competition in soluble Caco-2 homogenates. (D) 
Time-dependent oseltamivir competition in insoluble Caco-2 homogenates. (E) Higher 
substrate concentrations are more efficient at fluorophosphonate competition.
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Figure 2. Human CES1 inhibition by WWL50
(A) Chemical structures of WWL50 and WWL79. (B) FP-PEG-TAMRA competitive 
activity-based profiling of WWL50 in human Caco-2 homogenates highlights selective 
inhibition. (C) WWL50 is 100x more potent for recombinant human CES1 than recombinant 
human CES2. Error bars represented as standard deviations of 3-4 individual experiments.
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Figure 3. Identification of WWL50 targets in Caco-2 homogenates by ABPP-SILAC
Error bars represent SILAC ratio standard error quantified from tryptic peptides pooled from 
both soluble and membrane proteomes for two independent biological replicates. EST1 and 
EST2 are the human identifiers for CES1 and CES2, respectively.
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Figure 4. Inhibition of oseltamivir hydrolysis with CES1 inhibitors in Caco-2 homogenates
Results of time-dependent oseltamivir hydrolysis are shown as mean ± SEM.
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Figure 5. Ester prodrug hydrolysis in human HepG2 liver cell homogenates
(A) Fluorophosphonates and WWL50 block oseltamivir hydrolysis in HepG2 soluble and 
insoluble homogenates. (B) WWL50 blocks FP-PEG-TAMRA labeling of a 60 kD serine 
hydrolase in soluble and insoluble homogenates from HepG2 cells, corresponding to CES1. 
(C) FP-TAMRA, which replaces the PEG linker with an aliphatic linker, shows similar 
competition for a 60 kD serine hydrolase (CES1). (D) WWL50 blocks ethyl ester hydrolysis 
activity in HepG2 soluble homogenates. (E) Insoluble homogenates have reduced ethyl ester 
hydrolysis, but essentially all activity is blocked by WWL50. Enalapril (0.5 mM), benazapril 
(0.5 mM), tazarotene (0.25 mM) and valacyclovir (0.5 mM) were hydrolyzed at 37 °C in 
HepG2 cytosol (1 mg/ml) followed by quantitative HPLC analysis at different time points. 
Results are represented as the average ± SD of 2-3 individual experiments.
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Figure 6. Oseltamivir impedes the inactivation rate of CES1 by fluorophosphonates
(A) Substrate-dependent velocity of recombinant human CES1-catalyzed oseltamivir 
hydrolysis and associated steady-state kinetic parameters. (B) Time-dependent 
fluorophosphonate inactivation of recombinant human CES1 and the associated pseudo-
first-order rate constant. Near-saturating oseltamivir concentrations lead to a 4-fold 
reduction in the observed rate constant for fluorophosphonate inactivation of CES1. Error 
bars represent the standard deviation from 3-4 replicates.
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Figure 7. Covalent docking of WWL50 and 79 to human and mouse CES1
WWL50 and WWL79 were covalently docked to the catalytic Serine 221 in the crystal 
structure of human CES1 (PDB ID: 2H7C, colored orange) and the homology model of 
mouse CES1 (colored green). The active site rendered as surface was clipped to show the 
difference in alkylaminoacyl binding site volume across human and mouse CES1s. WWL50 
and 79 along with residues that differ between the human and mouse CES1 enzymes are 
shown as sticks. (A) WWL50 docked into the human CES1. (B) WWL79 docked into the 
human CES1. (C) WWL50 docked into to the mouse CES1 homology model. (D) WWL79 
docked into the mouse CES1 homology model.
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